A high-affinity, partial antagonist effect of 3,4-diaminopyridine mediates action potential broadening and enhancement of transmitter release at NMJs

3,4-Diaminopyridine (3,4-DAP) increases transmitter release from neuromuscular junctions (NMJs), and low doses of 3,4-DAP (estimated to reach ∼1 μM in serum) are the Food and Drug Administration (FDA)-approved treatment for neuromuscular weakness caused by Lambert–Eaton myasthenic syndrome. Canonica...

Descripción completa

Detalles Bibliográficos
Autores principales: Ojala, Kristine S., Ginebaugh, Scott P., Wu, Man, Miller, Evan W., Ortiz, Gloria, Covarrubias, Manuel, Meriney, Stephen D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Biochemistry and Molecular Biology 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7949096/
https://www.ncbi.nlm.nih.gov/pubmed/33465376
http://dx.doi.org/10.1016/j.jbc.2021.100302

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7949096/
https://www.ncbi.nlm.nih.gov/pubmed/33465376
http://dx.doi.org/10.1016/j.jbc.2021.100302

Ejemplares similares